Cantor Fitzgerald Predicts ALX Oncology FY2025 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for ALX Oncology in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($2.21) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.76) per share.

A number of other research analysts have also recently issued reports on ALXO. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of ALX Oncology in a research report on Wednesday, December 18th. Jefferies Financial Group downgraded shares of ALX Oncology from a “buy” rating to a “hold” rating and reduced their price target for the company from $12.00 to $2.00 in a research note on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.50.

ALX Oncology Trading Down 9.4 %

Shares of ALXO opened at $1.63 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. ALX Oncology has a 52-week low of $1.19 and a 52-week high of $17.83. The firm has a market cap of $85.97 million, a price-to-earnings ratio of -0.55 and a beta of 0.98. The business’s fifty day moving average is $1.61 and its 200-day moving average is $2.43.

Hedge Funds Weigh In On ALX Oncology

A number of hedge funds have recently modified their holdings of ALXO. Marshall Wace LLP raised its position in ALX Oncology by 423.0% during the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after purchasing an additional 514,133 shares during the last quarter. Privium Fund Management B.V. raised its position in shares of ALX Oncology by 28.2% during the third quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock worth $926,000 after acquiring an additional 112,093 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of ALX Oncology by 87.2% in the second quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock worth $2,642,000 after acquiring an additional 204,100 shares during the period. XTX Topco Ltd acquired a new position in shares of ALX Oncology in the third quarter worth approximately $578,000. Finally, Point72 Asset Management L.P. bought a new stake in ALX Oncology in the second quarter valued at approximately $1,834,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

Insider Buying and Selling at ALX Oncology

In other ALX Oncology news, Director Rekha Hemrajani bought 30,000 shares of ALX Oncology stock in a transaction on Monday, December 2nd. The shares were purchased at an average cost of $1.55 per share, with a total value of $46,500.00. Following the acquisition, the director now directly owns 33,000 shares of the company’s stock, valued at $51,150. The trade was a 1,000.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders sold 14,443 shares of company stock worth $23,309. 33.40% of the stock is currently owned by insiders.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.